[Reporter’s Notebook] Drug Price Cuts: Direction Comes Before Speed View original image

The government’s plan to lower drug prices is certainly reasonable. It is difficult to dismiss the logic that the attempt to adjust the prices of generics for the first time in 13 years is an inevitable step to ensure the sustainability of the National Health Insurance finances. The fact that the price of generics—currently at 53.55% of the original drugs—is high compared to major developed countries is not a new issue. Excessively high drug prices are likely to be passed on as a burden to the public. The real challenge, however, is how to address this issue.


The Emergency Response Committee, which includes seven pharmaceutical and biotech organizations such as the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, along with labor unions, held an urgent press conference on the 10th and proposed joint research between the government and the industry. They suggested first analyzing the impact that drug price reductions would have on public health and the industry structure, and then working together to develop implementation measures. The industry has stated that, if the policy is implemented as currently drafted, annual sales could decrease by as much as 3.6 trillion won. They also highlighted that, on top of this, the so-called 'fourfold hardship' of rising oil prices, exchange rates, raw material costs, and shipping rates due to the Middle East crisis has pushed cost pressures to their limits. Given the industry’s heavy reliance on imported active pharmaceutical ingredients, adverse external conditions are placing an additional burden on management. There are also growing concerns, both inside and outside the industry, that if drug prices are excessively lowered, the sector’s overall research and development (R&D) capacity will weaken, and in the long run, the entire country may end up bearing even higher costs.


The industry’s arguments are as valid as the government’s rationale. While it has been pointed out that the industry has often responded to government efforts to reduce drug prices by stalling for time and heightening public anxiety to escape a 'crisis,' this alone is not enough to reject the industry’s claims outright, given the significantly increased national importance of the pharmaceutical and biotech sector. What is particularly noteworthy is that the industry itself has indicated a willingness to accept a '10% reduction' as a feasible level, thereby leaving some room for dialogue. It is also worth paying attention to the criticism that implementing the revised plan, announced just last November, within a matter of months is too hasty from the industry’s perspective.



Beneath the keyword 'drug prices' lies a complex web of industrial·and policy factors that go far beyond the simple notion of product pricing. Issues such as the profit structure centered on generics and various regulations that undermine new drug development capabilities are deeply intertwined.Therefore, while the long-term goal of reducing drug prices should be maintained, it is important to join forces and focus on the bigger picture rather than becoming overly fixated on this single issue. If conclusions are drawn based on joint research that prioritizes direction over speed, the foundation for policy can become much stronger.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing